Shiyu Capital Leads USD278m Series A for Chinese Biopharma Mabwell

Chinese VC Shiyu Capital led a CNY1.97b (approximately USD278m) Series A for China-based biopharmaceutical company Mabwell Biotech. Oriental Fortune Capital, Loyal Valley Innovation Capital, Haitong Innovation Capital Management, Founder H Fund, Haurong Rongde Asset Management, Huajin Capital, Sincere Capital, and Winfast Holding also participated in the round. Read More



(default archive template)